

---

Astana, 19.9.2018

# Flow cytometry for the diagnosis of human immunodeficiency



Ulrich Sack, Leipzig University

*I thank Michael Borte, Andreas Boldt,  
Stephan Borte, and Aydan İkinçioğulları  
for slides and input*

## **Disclosure of Conflicts of Interest**

Membership in INSTAND e.V. and DGKL e.V.  
Technical Assessor for INAB and DAkkS  
IFCC WG-FC supported by Beckman-Coulter



## A Tradition of Crossing Boundaries

Campus on Augustusplatz at the start of the 20th century and the 21st century: "...in Leipzig something new is evolving which at the same time clearly brings our own history to mind." (Prof. Dr. Frank Zöllner)

## The second oldest

- 1409: founding of Universität Leipzig by masters graduates and professors from Prague



5

## International – open to the whole world

✓2,800 international students  
(10%) from 131 countries

✓320 ERASMUS  
partners

✓Student mobility: 3rd  
place worldwide in  
ERASMUS “outgoings”

✓80 agreements at university and  
faculty level worldwide

✓23 international courses

✓in contact with 2,000  
international alumni from  
more than 110 countries

Institut für Klinische Immunologie, Medizinische Fakultät der Universität

6



Institut für Klinische Immunologie, Medizinische Fakultät der Universität

## Significant alumni from Universität Leipzig

Wundt – Heisenberg – Ostwald – Hertz – Litt – Leibniz –  
Müntzer – Lessing – Goethe – Wagner – Nietzsche –  
Kästner ...

Today more than 150,000 alumni from Universität Leipzig  
live all over the world, including:

- *Hans-Dietrich Genscher*, 1946-1949, studied Law
- *Angela Merkel*, 1973-1978, studied Physics



## A flavour of Leipzig

Trading centre since 1165 – “the mother of all trade fairs”

New potential in the automotive and supply industry, biotechnology, and media and life sciences

Leipzig is the cradle of the 1989 Peaceful Revolution

Diverse cultural and student life:  
40,000 students among 500,000 inhabitants

Very reasonable accommodation  
and good quality of life



# Content


- Immunodeficiencies
- PID – rare diseases?
- Newborn screening for PID
- PID flow cytometry
- PID flow cytometric screening
- Functional testing

# Immunodeficiencies

- Secondary immunodeficiencies
  - Infectious?
  - Induced by malnutrition, chronic diseases, stress
  - Local focus on ID induced by HSCT, immunotherapies, irradiation, ...
- PID
  - Not only in children
  - Main topic in this presentation

# Introduction: PID classification and relevance

Primary immunodeficiency diseases (PIDs) are a genetically heterogeneous group of disorders affecting distinct components of the innate and adaptive immune system. Clinical representation is dominated by infectious diseases.



Disease Fact file OMIM  
 C1r deficiency 51 OMIM:216950  
 C1s deficiency 52 OMIM:120580  
 C2 deficiency 90 OMIM:217000  
 C3 deficiency 61 OMIM:120700  
 C4 deficiency

Disease Fact file OMIM  
 C4A deficiency 53 OMIM:120810  
 C4B deficiency 54 OMIM:120820  
 C5 deficiency 91 OMIM:120900  
 C6 deficiency 92 OMIM:217050  
 C7 deficiency 93 OMIM:217070  
 C8 deficiency

➔ more than **280** primary  
 immunodeficiency  
 diseases defined

Disease Fact file OMIM  
 C8 α-polypeptide deficiency 55 OMIM:120950  
 C8 β-polypeptide deficiency 56 OMIM:120960  
 C8 γ-polypeptide deficiency 57 OMIM:120930  
 C9 deficiency 94 OMIM:120940  
 Defects of the alternative complement pathway

Factor B deficiency 95 OMIM:138470  
 Factor D deficiency 98 OMIM:134350  
 Factor H1 deficiency 101 OMIM:134370  
 Properdin factor C deficiency 100 OMIM:312060, OMIM:300383  
 Defects of complement regulatory proteins

➔ immunodeficiency  
 signs part of countless  
 inherited diseases

Hereditary angioedema 97 OMIM:106100, OMIM:606860  
 C4-binding protein deficiency  
 Disease Fact file OMIM  
 C4 binding protein α deficiency 58 OMIM:120890  
 C4 binding protein β deficiency 59 OMIM:120831  
 Decay-accelerating factor (CD35) deficiency 102 OMIM:125240  
 Factor I deficiency 99 OMIM:217030  
 CD59 deficiency 103 OMIM:107271  
 Mannose-binding lectin deficiency

Disease Fact file OMIM  
 Mannose-binding lectin deficiency 96 OMIM:154545  
 Mannan-binding lectin - associated serine protease 2 deficiency 119 OMIM:605102  
 Periodic fever syndromes  
 Familial mediterranean fever 140 OMIM:608107  
 Hyperimmunoglobulinemia D with periodic fever syndrome 141 OMIM:260920, OMIM:251170  
 Tumor necrosis factor receptor-associated periodic syndrome 142 OMIM:142680, OMIM:191190  
 Cold autoinflammatory syndrome

Periodic fever syndromes

Familial mediterranean fever 140 OMIM:608107

Hyperimmunoglobulinemia D with periodic fever syndrome 141 OMIM:260920, OMIM:251170

Tumor necrosis factor receptor-associated periodic syndrome 142 OMIM:142680, OMIM:191190

Cold autoinflammatory syndrome

Disease Fact file OMIM

Familial cold urticaria and Muckle-Wells syndrome 143 OMIM:120100, OMIM:191900, OMIM:606416


Chronic infantile neurological cutaneous and articular syndrome 144 OMIM:307115, OMIM:606416

Granulomatous sinovitis with uveitis and cranial neuropathies 145 OMIM:186580, OMIM:605956




# Clinical Presentation/Natural Course

Severe



Mild/asymptomatic




# Classification of Primary Immunodeficiencies

- Combined B and T cell immunodeficiencies
- Predominantly antibody deficiencies
- Autoinflammatory disorders
- Diseases of immune regulation
- Defects of the innate immune system
- Defects of phagocyte number, function, or both
- Complement deficiencies
- Other well-defined immunodeficiencies
- Syndromes with PID


# Screening levels for primary immunodeficiencies




Symptomatology and  
clinical diagnostics



Single-cell  
function & phenotype



RNA species



Proteins and  
cellular intermediates

Genomic DNA  
and excision products



## Are PID really „rare“ diseases ?

- Rheumatoid arthritis 1 : 100-200
- Gluten enteropathy 1 : 200-800
- **Primary immunodeficiencies (PID) 1 : 250-500**
- Type 1 diabetes 1 : 600-800
- Multiple sclerosis 1 : 800-1000


# Diagnostic delay of all PID entities by age

| Age group | Diagnostic delay (years)<br>Median (IQR) | p value  |
|-----------|------------------------------------------|----------|
| < 16      | 1.2 (0.3, 4.6)                           | } <0.001 |
| 16 +      | 3.2 (0.8, 9.7)                           |          |


- Differing PID awareness of medical specialists AND patients
- Adult-onset of distinct immunodeficiency syndromes
- Single-gene defects vs polygenic / complex predisposition
- Epigenetic, environmental and iatrogenic factors

# Rationale of neonatal screening for SCID

Not diagnosed at birth



Diagnosis suspected at birth




## Severe Combined Immunodeficiency (SCID) is a Pediatric Emergency

Untransplanted patients die within  
the first year of life

Early (<3.5 months of age) identic/non-identic transplants  
are life saving

*Buckley RH et al. NEJM, 1999*



*1982-2011, 169 SCID*

***Age at transplant <3.5 mo (n=49): 94% live***

*3 pts. >30 yrs.*

# Newborn screening for severe PID

# Newborn screening for severe PID

## Clinical presentation

- Heterogeneous group of inborn disorders
- Lack of functional T cells +/- B and NK cells
- Overwhelming fungal, viral and bacterial infections
- Fatal <12 mo if undiagnosed and untreated
- Pediatric emergency

## Hallmarks applicable to neonatal screening

- Severe T cell lymphopenia
- Severe B cell lymphopenia

# „Screening“ for severe T-lymphopenia

## Biomarker analysis

- T lymphocyte  
correlated proteins  
(IL-7 ELISA,  
CD3/CD45 assay)
- *false negatives*


## Flow cytometry

- Surface markers
- *sample source*
  - *throughput ?*
  - *analysis ?*

## Molecular cytometry

- TRECs (T cells)
- KRECs (B cells)
- Signature transcripts

# Somatic recombination



- RAG1/2 proteins
- ligases






Figure 4.20 The Immune System, 3ed. (© Garland Science 2009)

# Genomic alterations in severe PID




# Thymic output correlates with TREC copy numbers



# KRECs represent the homeostatic replication of B cells

Correlation of absolute CD19+ B cell counts and KREC copy numbers




# TREC-KREC-ACTB screening assay

*Dried blood spot sample*



- regular Guthrie cards (e.g. 903 paper)
- single 3.2 mm dried blood spot punch

*Robotic sample processing*




- removal of PCR inhibitors
- heat-elution of genomic DNA

*Real-time quantitative PCR*




- real-time triplex PCR
- plasmid standard for absolute quantitation
- possibility for multiplexing

# Proof-of-principle (*retrospective study 2011*)



# Proof-of-principle (*retrospective study 2011*)




# Improved TREC-KREC assay *SCREEN-ID*

- Improved low-copy resolution
- Lowered cut-offs
- Reduced recall rate
- Reduced cost (€ 1.45 in our hands)




## SCREEN-ID workflow (~2 hrs)



|               |                                                                                                                                  |
|---------------|----------------------------------------------------------------------------------------------------------------------------------|
| Filter plate  | Rinsing of dried blood spots (15 min)                                                                                            |
| Elution plate | Elution of nucleic acids from the dried blood spots (30 min)<br><br>Filter plate is re-used to withdraw eluted dried blood spots |
| qPCR plate    | Absolute quantitation of TREC, KREC and beta-actin copy numbers using triplex-qPCR (60 min)                                      |

# TREC-KREC assay (*prospective study 2012*)




# The first XLA patient identified by newborn screening


Stockholm  
2012



*BTK* gene (exon 15)



# „False-positives“ in the TREC assay




- Genetic screening for PID can be misleading and must be confirmed and/or supplemented by flow cytometry.
- Occasionally, PID present independent on genetic screening

Needed:






- PID screening with flow cytometry

# Challenge # 1: missing reference ranges in children and highly individual findings



Challenge # 2: step-by-step approaches.

A) Risky: common immune status:




**„Immune status“:**


No information  
about maturation  
and function


→ We can miss PID!




Challenge # 2: step-by-step approaches.


B) expensive: various tubes needed:







**A****B****C**




Our proposal: Validation of a one-tube orientation approach


# New: novel Duracclone tube: 1 tube only

|               | Violet Excitation<br>(405nm) |              | Blue Excitation<br>(488nm) |        |         |           | Red Excitation<br>(633-640nm) |           |
|---------------|------------------------------|--------------|----------------------------|--------|---------|-----------|-------------------------------|-----------|
| Specificity 1 | CD4                          | CD45         | CD3                        | IgD    | CD27    | CD38      | CD16                          | CD19      |
| Clone 1       | 13B8.2                       | J33          | UCHT1                      | IA6-2  | 1A4CD27 | LS198-4-3 | 3G8                           | J3-119    |
| Specificity 2 | x                            | x            | x                          | CD45RO | x       | x         | CD56                          | CD8       |
| Clone 2       | x                            | x            | x                          | UCHL1  | x       | x         | N901                          | B9.11     |
| Fluorochrome  | Pacific Blue                 | Krome Orange | FITC                       | PE     | PC5.5   | PC7       | APC                           | APC-AF750 |


# Principal populations




## T Cell subpopulations




## B Cell subpopulations



## NK Cell subpopulations



## Monocyte subpopulations



# Conclusion

The presented antibody panel is a potent candidate for a rapid primary immune deficiency screening tool in the immunology lab:

- easy implementation due to pipetting-free dry panel format, no-wash protocol
- comprehensive information on cellular proportions / concentrations
- coverage of important late cellular differentiation stages
- compatibility with common instrumentation

Also, secondary immune deficiencies may be subject to this rapid screening method. Further work will now focus on cross-instrument standardization.

## Functional T cell phenotyping in PID


## Challenge # 3: Functional aberrations in immune cells

# Clinical case: a baby-girl with severe fungal infections




- Treatment-resistant diaper candidiasis
- 2 episodes of pneumonia in 1st y of life

# Clinical case: pedigree




# Chronic mucocutaneous candidiasis: disease mechanisms



# Analysis of Th17 cells (ICS, PMA+Iono)


healthy  
sibling




patient

# Analysis of specific Th17 responses

Leucocytes cultured in presence of HKCA for 3 days




healthy  
sibling




patient

# Lack of Th17 cells and CMC ?




healthy sibling



*STAT1* gene  
c.1154 C>T (he)

# STAT1 deficiency and clinical phenotypes



**Red:** AD: CMC phenotype


**Blue:** AR: MSMD/viral phenotype (partial STAT1 deficiency)

**Green:** AD: MSMD phenotype (partial STAT1 deficiency)


**Brown:** AR: MSMD/viral phenotype (complete STAT1 deficiency)

# STAT1 p.T385M is a gain-of-function mutation

constitutive STAT1 phosphorylation  
(anti-pTyr701 Ab)



Lymphocytes +/- IFN $\gamma$  für 3h  
20  $\mu$ g Lysate per lane



BD Phosflow pSTAT1  
staining of CD4<sup>+</sup> T cells

# Challenges for laboratories

- Clinical question? → clinical answer!
- Clinical advisory services
- Consider partial independency between lab findings and pathological consequences
- In children very broad reference ranges
- Severe therapeutic consequences!
- Cave surrogate markers!
- Precious blood samples
- Proficiency testing

# Conclusions

- Increasing need for immune diagnostics
- Clinical awareness crucial
- Frequent diseases but heterogeneous ones
- Relevant findings for therapeutic decisions
- Disadvantages of initial screening tests

**Thank you very much!**



<http://ikit.uniklinikum-leipzig.de>; +49 341 97 25500

**Institut für Klinische Immunologie, Medizinische Fakultät der Universität Leipzig**